Table 1.

Clinical efficacy data from LUX-Lung 3

	Afatinib arm	Pemetrexed-cisplatin arm
Median overall survival, months (95% CI)	28.2 (24.6–33.6)b	28.2 (20.7–33.2)b
Median first-line progression free survival, monthsa	11.1c	6.7c

CI confidence interval

^a95%CI was not reported

Source: ^b Yang et al., [12]; ^cSequist et al, [6]